anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hearing-impaired persons with asymmetric hearing loss and a unilateral indication for a cochlear implant (CI) generally benefit from a bimodal hearing solution. The influence of bimodal fitting on speech comprehension (SC) over time has not yet been sufficiently investigated. The present study examines the influence of bimodal fitting on SC in bimodally fitted CI users with postlingual deafness at least 36 months after implantation and analyzes possible influencing factors.
METHODS: Included in this retrospective longitudinal study were 54 bimodally fitted speech-competent CI users with at least 36 months of CI experience. Audiometric data of these CI users at predefined timepoints were compared.
RESULTS: The change in the results of the Freiburg monosyllabic test (FT) over 36 months was significant (p < 5%) for the deafness group at <10 years for both the 65 dB sound pressure level (SPL) and at 80 dB SPL and also significant for the deafness group ≥10 years for 65 dB SPL. In the Oldenburg sentence test (OlSa) there was a highly significant change (p < 0.1%) for S0, S0N0, and S0NCI configurations and a very significant change (p < 1%) for S0NHA (HA: hearing aid). Age at implantation as a possible influencing factor could not be confirmed in the FT. In contrast, the duration of deafness was a negative influencing factor for SC with CI in the FT, whereas a longer duration of deafness was associated with worse results in the FT. The degree of hearing loss in the ear fitted with an HA did not influence SC. The median bimodal benefit (here: difference in SC with bimodal fitting compared to unilateral HA fitting for FT at 65 dB SPL) was 10% over the total study period. For a median of 79% of the test subjects, the bimodal benefit was found over the entire period of 36 months.
CONCLUSION: Over time, SC improves significantly with a CI for the bimodal test subjects. The investigated influencing factors (age, duration of deafness, and degree of hearing loss in the contralateral ear) support the indication for bimodal provision in accordance with the guideline in Germany for cochlear implantation-regardless of age, duration of deafness, and hearing ability of the contralateral ear.
FIELD: medicine; biotechnology.SUBSTANCE: described is a method for treatment of a patient with cancer expressing a tumour-associated antigenic protein MAGEA3, an isolated Maraba MG1 virus particle and a first virus. Said particle contains nucleic acid that is capable of expressing the tumour-associated antigenic protein MAGEA3. Said antigenic protein contains an amino acid sequence that is at least 70 % identical to SEQ ID NO: 1, and includes at least one tumour-associated MAGEA3 epitope selected from the group consisting of: FLWGPRALV (SEQ ID NO: 27), KVAELVHFL (SEQ ID NO: 28), EGDCAPEEK (SEQ ID NO: 35), KKLLTQHFVQENYLEY (SEQ ID NO: 36) and RKVAELVHFLLLKYR (SEQ ID NO: 37). Said antigen protein is able to induce an immune response in a specified patient in a heterologous prime-boost format. This first virus is an adenovirus containing nucleic acid capable of expressing the tumour-associated antigenic protein MAGEA3. Said antigenic protein contains an amino acid sequence that is at least 70 % identical to SEQ ID NO: 1, and includes at least one tumor-associated MAGE A3 epitope selected from the group consisting of: FLWGPRALV (SEQ ID NO: 27), KVAELVHFL (SEQ ID NO: 28), EGDCAPEEK (SEQ ID NO: 35), KKLLTQHFVQENYLEY (SEQ ID NO: 36) and RKVAELVHFLLLKYR (SEQ ID NO: 37). Described is an oncolytic heterologous viral prime-boost vaccine for treating a patient with cancer and the use of an isolated viral particle Maraba MG1 for the induction of an immune response in a patient in a heterologous prime-boost format for oncolytic viral therapy.EFFECT: invention allows to expand the range of agents and methods used for oncolytic viral therapy.33 cl, 9 dwg, 4 tbl, 10 ex
PURPOSE: To obtain a bonding composition for dental use, containing a potassium salt having desensitizing actions and a polymerizable monomer in combination, capable of moderating the pain caused during and after treatment of teeth and having the adhesiveness. CONSTITUTION: This bonding composition for dental use is obtained by combining a potassium salt having desensitizing actions with a polymerizable monomer or further with an aqueous medium or a polymerization initiator. A potassium salt selected from potassium chloride, potassium fluoride, potassium nitrate, potassium sulfate, potassium carbonate, potassium benzoate and potassium oxalate is preferred as the potassium salt. An acrylic or a methacrylic ester is preferred as the polymerizable monomer. When an aqueous medium is added to a system comprising the potassium salt and polymerizable monomer, a dentinal bonding primer composition is obtained. When the polymerization initiator is added to the system, a curable composition is obtained. The restoring treatment of teeth and treatment of pain in dental pulp or hyperethesia can integrally be carried out.
Disclosed is a novel composition which has an effect on promoting production of collagen. The composition has high photostability and is free from side effects such as those of retinoids. Specifically disclosed is a composition for promoting collagen production which contains one or more compounds selected from the group consisting of D-aspartic acid, D-alanine, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin a condition. The skin condition may include but is not limited to photoaging and/or wrinkles. The composition may be used for an external preparation for the skin or food. The composition may be a composition for promoting type I collagen production.
Normal individuals and persons heterozygous for cystinosis have white cell cystine levels of < 0.2 and usually below 1 nmol/½ cystine/mg protein, respectively. Individuals with nephropathic cystinosis have elevations of white cell cystine above 2 nmol/½ cystine/mg protein. White cell cystine is monitored in these patients to determine adequacy of dosing, levels being measured 5 to 6 hours after dosing. In the Long-Term Study (see Clinical Trials, below) entry white cell cystine levels were 3.73 nmol/½ cystine/mg protein (range 0.13 to 19.80 nmol/½ cystine/mg protein) and were maintained close to 1 nmol/½ cystine/mg protein with a cysteamine dose range of 1.3 to 1.95 g/m2/day. After administration of cysteamine HCl, leukocyte cystine levels fall, with minimum levels at approximately 1 hour.

Because cysteamine HCl has an unpleasant taste and odor, other formulations have been developed, including phosphocysteamine, the phosphorothioester of cysteamine that is rapidly converted to cysteamine in the gut, and cysteamine bitartrate (CYSTAGON®). Cysteamine bitartrate has been shown in a transfer study in 8 patients to maintain white cell cystine levels below 1 nmol/½ cystine/mg protein when substituted for cysteamine HCl or phosphocysteamine. Total cysteamine levels 2 and 6 hours post-dosing were higher after cysteamine bitartrate than for the solutions.

The pharmacokinetics and pharmacodynamics of CYSTAGON® were studied in eleven pediatric patients with nephropathic cystinosis who received 225 to 550 mg of cysteamine bitartrate every 6 hours daily for more than one year. Following repeated oral administration of 225 to 550 mg cysteamine bitartrate, the mean time to maximum plasma concentration (Tmax) occurred at about 1.4 hours post dose with mean steady-state peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of 2.6 µg/mL and 6.3 µg∙hr/mL, respectively. The apparent volume of distribution and apparent plasma clearance of cysteamine were 156 L and 1.2 L/min, respectively.

Cysteamine was moderately bound to human plasma proteins, predominantly to albumin, with mean protein binding of about 52%. Plasma protein binding was independent of concentration over the concentration range achieved clinically with the recommended doses. 

The pharmacodynamic response increased with the plasma cysteamine concentration, with maximum response occurring approximately 1.8 hours post dose with an average reduction of white cell cystine concentration of about 0.46 nmol/½ cystine/mg protein and returning to baseline level 6 hours post dose.

The mean white cell cystine concentration and mean cysteamine plasma concentration-time profile is shown below:

Most clinical data have been developed using cysteamine HCl or phosphocysteamine solutions. In all discussions that follow, administered amounts of various cysteamine salts will be expressed as amounts of cysteamine free base.
Participants will receive a single oral dose of either New Paracetamol Oral Suspension (24 mg/ml) or Panadol B\&I Oral Suspension (24 mg/ml paracetamol) on Day 1 (Period 1) and Day 4 (Period 2) under fasting conditions as per the randomization schedule. A wash out period of at least 72-hour will be maintained between each treatment period.
Subjects will receive AK119 and AK112 plus pemetrexed and carboplatin via intravenously (IV) Q3W, up to 4 cycles. Afterward, AK119 and AK112 plus pemetrexed will continue to be treated up to 2 years.
Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
Headings purpose: Fibromyalgia (FM) is a chronic, nondegenerative disease with important limitations in patients. Its average global prevalence is 1.78%, and women are more affected than men (3:1). Due to the lack of objective diagnostic tools, it is a complex medical condition that is frequently unseen by patients' relatives and doctors, which might nonetheless have a noticeable impact on the patient's entourage. Material and Methods: This qualitative descriptive study aimed to elicit family members' views on how FM affects their lives. It was conducted in two community health centers (one rural and one urban) from the Sagunto Health Department (Valencia Community, Spain). We included seven focus groups with 41 family members. We analyzed the data gathered with an inductive thematic semantic analysis approach using NVivo 12 software. Results: We identified four major themes: (1) fibromyalgia as a nosological entity or an invention that is always burdensome; (2) children and spouses as caregivers (or not); (3) adverse effects of fibromyalgia on the couple's sexual life; and (4) harmful consequences of FM on the family economy. The findings showed a negative impact of the disease within the family context. Family members face complex and changing roles and difficulties when living with women with fibromyalgia. Conclusions: Relatives' better understanding of the disease, greater acceptance of new family roles, and improvement of patients' work conditions are all interventions that may help reduce the negative impact of FM in the family context.
All patients will initiate open-label treatment with pasireotide LAR on week 1 in the outpatient setting. Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days. Administration of pasireotide will align with package inset. Patients must return to the study center every 28 days (+/- 7 days) to receive study medication and for evaluation.
The strength and balance activities of the LiFE program will be carried out. Participants will be invited to participate in groups of about 8 - 12 people in community venues.
Arm A: 18-26 years old. Random, double blind, Gardasil®9 positive control and placebo control was conducted in 120 healthy women in the arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : placebo: Gardasil® 9=3:1:1.Arm B: 27-45 years old. Random, double blind, Gardasil® positive control and placebo control was conducted in 120 healthy women in the arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first dose of the low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to be inoculated in the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. SCT1000 in each dose group: placebo: Gardasil® =3:1:1.Two arms can be recruited at the same time. If the DSMB assessment shows that the adverse events of a certain dose group meet the criteria of suspension / termination, the dose group will be suspended / terminated, and the vaccination of this dose group or higher dose group will not be carried out, and the study of other dose groups will continue. If this happens at a low dose, the study will be suspended / terminated.
BACKGROUND: Chat Generative Pre-trained Transformer (ChatGPT) is a new machine learning tool that allows patients to access health information online, specifically compared to Google, the most commonly used search engine in the United States. Patients can use ChatGPT to better understand medical issues. This study compared the two search engines based on: (i) frequently asked questions (FAQs) about Femoroacetabular Impingement Syndrome (FAI), (ii) the corresponding answers to these FAQs, and (iii) the most FAQs yielding a numerical response.
PURPOSE: To assess the suitability of ChatGPT as an online health information resource for patients by replicating their internet searches.
STUDY DESIGN: Cross-sectional study.
METHODS: The same keywords were used to search the 10 most common questions about FAI on both Google and ChatGPT. The responses from both search engines were recorded and analyzed.
RESULTS: Of the 20 questions, 8 (40%) were similar. Among the 10 questions searched on Google, 7 were provided by a medical practice. For numerical questions, there was a notable difference in answers between Google and ChatGPT for 3 out of the top 5 most common questions (60%). Expert evaluation indicated that 67.5% of experts were satisfied or highly satisfied with the accuracy of ChatGPT's descriptions of both conservative and surgical treatment options for FAI. Additionally, 62.5% of experts were satisfied or highly satisfied with the safety of the information provided. Regarding the etiology of FAI, including cam and pincer impingements, 52.5% of experts expressed satisfaction or high satisfaction with ChatGPT's explanations. Overall, 62.5% of experts affirmed that ChatGPT could serve effectively as a reliable medical resource for initial information retrieval.
CONCLUSION: This study confirms that ChatGPT, despite being a new tool, shows significant potential as a supplementary resource for health information on FAI. Expert evaluations commend its capacity to provide accurate and comprehensive responses, valued by medical professionals for relevance and safety. Nonetheless, continuous improvements in its medical content's depth and precision are recommended for ongoing reliability. While ChatGPT offers a promising alternative to traditional search engines, meticulous validation is imperative before it can be fully embraced as a trusted medical resource.
Octreotide Acetate Injection is available in 1 mL single-dose vials as follows:

Storage   
For prolonged storage, Octreotide Acetate Injection single-dose vials and multiple dose vials should be stored at refrigerated temperatures 2°C to 8°C (36°F to 46°F) and protected from light. At room temperature (20°C to 30°C or 70°F to 86°F), Octreotide Acetate is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Single-dose vials should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.
Quitting smoking appears to be the single most effective intervention or treatment to reduce mortality in patients with Coronary Heart Disease (CHD). However, despite interventions, almost two-thirds of smokers resumed smoking in the year after hospitalization for CHD related illnesses; one-third resumed smoking within one month. A critical challenge for institution-level programs is how to provide consistent patient follow-up and linkage to community-based smoking cessation resources. Interactive voice response (IVR) technology has the potential to improve follow-up with smokers after hospitalization and to enhance triage to clinical support for smoking cessation. IVR uses natural language to place automated out-going calls that can pose questions regarding smoking status and progress with smoking cessation, that is then dropped into a database. A counselor is then able to link with the database and obtain information about the patient's smoking cessation needs and provide support as appropriate. A randomized control trial (RCT) is planned to evaluate whether an IVR system for follow-up and triage helps smokers hospitalized for CHD, quit smoking over 26- and 52-week follow-up periods. Participants are randomized into either a Usual Care or IVR group. Both groups will receive in-patient counseling and offer of nicotine replacement therapy. The IVR group will additionally receive a telephone call from the IVR system three, 14, 30, 60, 90, 120, and 150 days after hospital discharge. Variables that will be assessed at 26 and 52 weeks include: smoking status, both 7-day point-prevalent and continuous abstinence, as well as self-efficacy for smoking cessation, use of effective cessation resources and patient satisfaction (at 26 weeks).
The study will consist of 3 periods: screening(up to 7 days), treatment and follow-up(up to 3 months). Subjects are assigned in a 1:1 ratio to Anfibatide or placebo during plasma exchange with the use of a computerized randomization schedule. The administration is 5 IU/60kg intravenous infusion and 0.002 IU/kg/h continuous intravenous infusion. Plasma exchange as the main treatment method is performed daily on the 5th day of solstice and then adjusted to every other day. Fresh frozen plasma（FFP）and cryoprecipitate-reduced plasma are preferred. Subjects will receive the study drug immediately after daily plasma exchange.
The study will be a randomized controlled trial and will be conducted in Jinnah hospital, Lahore. This study will be completed in time duration of 10 months after the approval of synopsis. Non probability convenience sampling technique will be used and 35 participants will be recruited in study after randomization. The subjects will be divided into two groups and the group A will receive manual lymph drainage and group B will receive massage whereas cold pack will be used as a baseline treatment. The tools that will be used for pre and post treatment assessment are NPRS, 6 point self rated engorgement scale and breast feeding self efficacy questionnaire. The data will be assessed after 5 days of treatment using 2 tailed t test. After data collection data will be analyzed by using SPSS version 25.
The study is a randomized controlled, double blind, parallel trial. A 4-week run-in period with refined wheat (RW) products will be included prior to the intervention for all subjects. Thereafter, two different treatments will be evaluated e.g. a 12-week intervention with whole grain wheat (WGW) products (98g of WGW per day) and a 12-week control intervention with RW products. Two experimental visits will be planned before and two experimental visits will be planned after the 12-week intervention period. In the first experimental visit the investigators will determine liver fat and abdominal fat distribution by magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI). In the second experimental visit the investigators will comprehensively phenotype the participants which will include the response to a mixed meal challenge test.
The invention provides novel methods and compositions for modulating type I muscle formation through modulation of PGC-1.alpha. activity or expression. Also provided are methods for identifying compounds that modulate type I muscle formation through modulation of PGC-1.alpha. activity or expression. Further provided are methods for treating disorders associated with type I and/or type II muscle formation, as well as transgenic animals expressing PG C- 1.alpha. in muscle.
Up to now, there has been to uniform case definition for the metabolic syndrome. The World Health Organization and the Third Report of the National Cholesterol Education Program's Adult Treatment Panel (ATP III), and Bureau of Health Promotion, Taiwan proposed different criteria for the metabolic syndrome. Therefore, the secondary objective is to evaluate the agreement between these criteria and the prevalence of concordant and discordant according to different criteria. Three thousand persons will be randomly selected from resident of Taichung City. All the participants will fulfill a structured questionnaire. Blood pressure, anthropometric variables are measured. Biochemical markers are analyzed by a biochemical autoanalyzer. Kappa will be used to estimate the agreement between different criteria.
Reference imagery of dermatological conditions is compiled in a crowd-sourced database (contributed by clinicians and/or the lay public), together with associated diagnosis information. A user later submits a query image to the system (e.g., captured with a smartphone). Image-based derivatives for the query image are determined (e.g., color histograms, FFT-based metrics, etc.), and are compared against similar derivatives computed from the reference imagery. This comparison identifies diseases that are not consistent with the query image, and such information is reported to the user. Depending on the size of the database, and the specificity of the data, 90% or more of candidate conditions may be effectively ruled-out, possibly sparing the user from expensive and painful biopsy procedures, and granting some peace of mind (e.g., knowledge that an emerging pattern of small lesions on a forearm is probably not caused by shingles, bedbugs, malaria or AIDS). A great number of other features and arrangements are also detailed.